Transcript France’s Therapeutic Innovations Cluster

The BioValley cluster in
Alsace: your gateway to
Europe
What is BioValley ?
• BioValley®, a unique trinational
life sciences cluster
What is BioValley ?
OFFENBURG
4.3 Millions
inhabitants
350 companies
(Pharma / biotech)
KONSTANZ
40.000 employees
(Life Science field)
What is Alsace BioValley?
What is Alsace Biovalley ?
• 9 complementary structures …
•
•
•
•
•
•
•
•
•
Alsace International
ADIRA
CAHR
ARI
CEEI
CONECTUS
Technopole
SEMIA
Association pour le développement de la filière
Sciences de la vie – Santé en Alsace
What is Alsace Biovalley ?
•Non for profit association dedicated to the development
•of Life Sciences in Alsace
 Funded by central and regional government
 Coordinator of the Tri-national BioValley cluster
 One of the 3 main LifeScience cluster in France
 Member of the LifeScience Corridor France
Our mission
•Accelerate the discovery and the development of
therapeutic innovations by:
1. Supporting innovative R&D projects
2. Structuring and improving the environment
Our mission
•Accelerate the discovery and the development of
therapeutic innovations by:
1.
2.
3.
4.
5.
Supporting innovative R&D projects
Structuring and improving the environment
Fostering the creation of new activities
Provide services to members
Attracting foreign businesses
1. Supporting innovative projects
2 priorities:
1. New therapeutic compounds
2. Medical Technologies
Figures:
Coût total projets
Financement demandé
Total financement obtenu
Auto financement
Répartition :
FUI
ANR
Oseo
Région Alsace
Conseil Général 67
Conseil Général 68
CUS
Année 1
Année 2
Année 3
(Août 2005 à Août 2006)
(Sept. 2006 à Août 2007)
(Sept. 2007 à Août 2008)
25 871
11 405
11 762
14 109
41%
37%
6%
13%
0%
1%
3%
17 853
8 971
6 921
10 932
26%
13%
18%
30%
1%
1%
6%
37 436
17 084
7 227
30 209
52%
0%
11%
19%
0%
0%
3%
Total
Répartition
81 160
37 460
25 910
32%
55 250
68%
2. Structuring the environment
– Fast
and
easy
access
to
public
research
opportunities through our unique «one stop shop»:
Conectus
– A set of high quality technology platforms to provide
services to industry (proteomics, DNA chips,
Imaging, phenotyping, genetic engineering…)
– Adapted infrastructures and services : Office and lab
spaces, Bio-incubators, start-up coaching programs,
etc.
2. Structuring the environment
All key competencies along the Drug Development value chain
3. Fostering the creation of new activities
DETECTION
1.
2.
3.
4.
Dropplet
BiorLink
Primabio
Biomica
PRE-INCUBATION
1. RDC Ther.
2. Urolead
3. Theleme
Winner of the Young Innovative
Company Creation contrest
INCUBATION
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Admesys
Acrylian
Digital Trainers
Rhenovia
Biowind
Sextant
Ginkgo
RB Nano
KLC-T
Zephir
Anvebor
Diagalz
SIP Com
X.techno
Decide Med.
eNovalys
Cell Prothera
Ubertone
Firalis
Clad
Green Ing.
POST-INCUBATION
1.
2.
3.
4.
Phosylab
Koffeeware
Agate
Phytodia
4. A comprehensive set of services
• Partnership Identification
• Project engineering and financial engineering
• Shared Business development
• Scientific and competitive intelligence
• International development and promotion
• Communication
Why have so many companies
chosen Alsace BioValley?
1. A gateway to European market
A great accessibility
•
2+3 international airports: EuroAirport Basel Mulhouse
Fribourg and Strasbourg International Airport. Many
connections with Paris Frankfurt and Zurich hubs.
•
•
•
High speed train links (TGV East European
and TGV Rhin-Rhône) : Strasbourg-Paris
in 2h20 (1h50 in 2012).
•
The Rhine River: the most important navigable
waterway in Europe. 40 hours downstream to Rotterdam
from Strasbourg Port and a direct connection to the
Danube River.
•
4th region in France for rail freight
•
2nd in France for broadband coverage
Great penetration of the European
pharma-biotech market
Nb of biotech companies
(source AFII)
Production of pharmaceuticqal products
Why have so many companies
chosen Alsace BioValley?
2. A world class education and
research environment
World-class research institutes
CHEMISTRY
GENETICS &
MOLECULAR BIOLOGY
ONCOLOGY,
SURGERY & ROBOTICS
A rich and structured academic environment
Why have so many companies
chosen Alsace BioValley?
3. A unique service and Business
Environment
An attractive set of national financial incentives…
Business performance
Strasbourg
YIC*
140
Dublin
Cambridge
120
Strasbourg
100
Paris
Milano
80
R&D cost
60
40
Copenhagen
Vienna
Erlang
20
0
Basel
*YIC= Young Innovative Company Status
Skåne
…completed by tailored financial engineering
Abroad
France
Administrative support
RainDance Technologies
RainDance
ISIS
Technologies (Pr. A. Griffith)
France
Sanofi
Aventis
Development of new High Throughput screening
technology using microfluidic systems
…completed by tailored financial engineering
Abroad
France
Administrative support
Affiliate
Headquarters
Total
Total cost of the project
470,000 €
Affiliate
240,000 €
University
230,000 €
95,000 €
Marginal cost for University
University
Public funding
215,000 €
120,000 €
95,000 €
Net cash required
120,000 €
120,000 €
0€
R&D
collaborative
program
How to increase our visibility
at the international level?
The Lifescience Corridor France
What is the Lifescience Corridor France ?
LFC represents more than
1,200 companies
involving > 80,000 jobs
A unique and broad
approach throughout the
continuum of Cancer
> Prevention, diagnostic,
treatment
Facing the challenges of
tomorrow’s healthcare
> Bio Pharmaceuticals :
from chemistry and
genes towards drugs
> Medical Technologies :
medical and surgical
devices, imaging and
robotics
Building a healthcare
shiled
to fight infectious
diseases
> Diagnostic, vaccines
& new therapies, Systems
October 2008
25
CANCER-BIO-SANTE CLUSTER
October 2008
26
a BIO CLUSTER led by industrial firms
Public
Healthcare
Scope
Core
Business
Targeted
Markets
Building a “healthcare shield” to fight human and
animal infectious diseases and viral-induced cancers
Developing innovative diagnostic, preventive and
therapeutic solutions and delivery systems for more
responsive & personalized medicine
Infectious Diseases, Viro-induced Cancers, Autoimmune Diseases, Orphan Diseases and Inflammatory
Diseases
Stakeholders
October 2008
27
Alsace Biovalley: triggering Therapeutic
Innovations
Life Sciences
Chemical Sciences
Targeted therapies
Developing
New Drugs
Therapeutic Innovations
combining technologies
and Life Sciences
Markers
Imaging
Preclinical
experiment
Developing Innovative
tools for medecine
Physics, photonics, NICT…
October 2008
28
Coordinated operations in 3 target countries:
Canada
 Lead partner: Alsace BioValley
 Ongoing collaboration with CQVB in Quebec
US
 Lead partner: Lyon Biopole
 M.O.U. with Massachussetts Office of International Trade
and Investment (MOITI) and Massachussetts Technology
Transfer Centre (MTTC)
Japan
 Lead partner: Cancer BioSanté
 Collaboration agreement with Kobe-Kansai
October 2008
29
Simplified access to:
Technological partnerships
 Academic research institutes and Biotech companies
 Multiple source of funding
Technology Transfer Opportunities
 One stop shopping for all TTOs
Establishment of European subsidiaries
 Direct link with Economical development agencies
 National and regional financial incentives
October 2008
30
A unique pool of potential partners in the French
industry
October 2008
31
Thank you for your attention
Fabien Sebille
[email protected]
Tel : +33 (0) 3 90 40 30 00
www.alsace-biovalley.com
www.biovalley.com